Movement toward Optimization of CLL Therapy

Improved therapeutic approaches in chronic lymphocytic leukemia (CLL) have recently attracted special attention, not only from hematologists and oncologists but also from a large segment of the medical profession, because findings in this disease can affect several other diseases. One important aspect of recent advances in CLL therapy, which has been regularly neglected by past investigators, is that the disease primarily affects the elderly population, with a median age at diagnosis of 72 years and with multiple clinically significant coexisting conditions. This neglect is unfortunate, but it is understandable because it stems from safety concerns that an elderly patient with . . .